Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).

Shachar Peles, MD, Nicholas M. Fisher, Steven M. Devine, MD, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD

Blood (2005) 106 (11): 3237.

https://doi.org/10.1182/blood.V106.11.3237.3237

Published: 2005

Journal Articles

Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.

Shachar Peles, MD, Nicholas M. Fisher, Feng Gao, MD, PhD, Steven M. Devine, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD.

Blood (2005) 106 (11): 3458.

https://doi.org/10.1182/blood.V106.11.3458.3458

Published: 2005

Journal Articles

Bortezomib Does Not Impair Cytokine Induced Mobilization of Stem Cells Prior to Autologous Transplantation in Multiple Myeloma.

Geoffrey L. Uy, MD, Nicholas M. Fisher, BS, Steven M. Devine, M.D, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD

Blood (2005) 106 (11): 2926.

https://doi.org/10.1182/blood.V106.11.2926.2926

Published: 2005

Journal Articles

Bortezomib Alters Peripheral Blood Lymphocyte Subsets in Patients with Multiple Myeloma.

Geoffrey L. Uy, MD, Matthew S. Holt, BS, Nicholas M. Fisher, BA, Steven M. Devine, MD, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD

Blood (2005) 106 (11): 2387.

https://doi.org/10.1182/blood.V106.11.2387.2387

Published: 2005

Journal Articles

Bortezomib Given in Sequence with Anthracycline and Thalidomide-Containing Regimens Does Not Adversely Affect Stem Cell Mobilization and Engraftment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Geoffrey L. Uy, M.D., Nicholas M. Fisher, B.S., Steven M. Devine, M.D., Hanna J. Khoury, M.D, Douglas R. Adkins, M.D., Michael H. Tomasson, M.D, Timothy A. Graubert, M.D., John F. DiPersio, M.D., Ph.D., Ravi Vij, M.D.

Blood (2004) 104 (11): 541.

https://doi.org/10.1182/blood.V104.11.541.541

Published: 2004

NARROW

Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).

Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.

Bortezomib Does Not Impair Cytokine Induced Mobilization of Stem Cells Prior to Autologous Transplantation in Multiple Myeloma.

Bortezomib Alters Peripheral Blood Lymphocyte Subsets in Patients with Multiple Myeloma.

Bortezomib Given in Sequence with Anthracycline and Thalidomide-Containing Regimens Does Not Adversely Affect Stem Cell Mobilization and Engraftment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).

Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.

Bortezomib Does Not Impair Cytokine Induced Mobilization of Stem Cells Prior to Autologous Transplantation in Multiple Myeloma.

Bortezomib Alters Peripheral Blood Lymphocyte Subsets in Patients with Multiple Myeloma.

Bortezomib Given in Sequence with Anthracycline and Thalidomide-Containing Regimens Does Not Adversely Affect Stem Cell Mobilization and Engraftment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only